Our Science and Technology
Rooted in a Deep Understanding of Genetics
The genetic basis of human disease continues to inspire our science and technology as we expand to new therapeutic approaches, while our industry-leading chemistry helps us target the right medicine to the right disease – providing a rich source for future breakthroughs and transformative impact.
WHO WE ARE
Ionis unites groundbreaking science and technology with relentless passion to discover and deliver medicines that enable better futures for people living with serious diseases.
Our commitment to changing lives is a calling that pushes us to deliver the next solution for patients and those who care for them.
We have set our sights on providing new solutions across the spectrum of diseases, from common intractable neurologic conditions to cardiometabolic disorders and select areas of high patient needs.
We push beyond the impossible to unleash the potential of patients – and those who care for them – enabling them to make their own impact on the world.
We believe operating responsibly and sustainably creates long-term value and a positive impact for our company, stakeholders, patients, communities and the broader world.
JOIN OUR TEAM
Seizing the Moment to Unlock the Potential of RNA- and DNA-Targeted Medicines
If you’re driven to deliver on the promise of groundbreaking medicines that empower patients and caregivers to make their own impact on the world, come join us.
LATEST NEWS FEED
Ionis announces positive topline results from pivotal study of zilganersen in Alexander disease
– First and only investigational medicine to demonstrate a clinically meaningful and disease-modifying impact on this rare, often fatal neurological condition – – NDA submission planned in Q1 2026 – CARLSBAD, Calif. --(BUSINESS WIRE)--Sep. 22, 2025-- Ionis Pharmaceuticals, Inc.
TRYNGOLZA® (olezarsen) approved in the European Union for familial chylomicronemia syndrome (FCS)
CARLSBAD, Calif. --(BUSINESS WIRE)--Sep. 19, 2025-- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) and Sobi® today announced that TRYNGOLZA® (olezarsen) has been approved in the European Union (EU) as an adjunct to diet in adult patients for the treatment of genetically confirmed familial
Ionis expands Surf Away+ event, marking 10 years of creating unique adaptive experiences for people with neurological diseases
CARLSBAD, Calif. --(BUSINESS WIRE)--Sep. 12, 2025-- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today celebrated 10 years of Surf Away+, an inclusive adaptive event for rare neurological disease communities. Originally created with the goal of providing people with spinal muscular atrophy (SMA)
Ionis announces positive topline results from pivotal study of zilganersen in Alexander disease
– First and only investigational medicine to demonstrate a clinically meaningful and disease-modifying impact on this rare, often fatal neurological condition – – NDA submission planned in Q1 2026 – CARLSBAD, Calif. --(BUSINESS WIRE)--Sep. 22, 2025-- Ionis Pharmaceuticals, Inc.
TRYNGOLZA® (olezarsen) approved in the European Union for familial chylomicronemia syndrome (FCS)
CARLSBAD, Calif. --(BUSINESS WIRE)--Sep. 19, 2025-- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) and Sobi® today announced that TRYNGOLZA® (olezarsen) has been approved in the European Union (EU) as an adjunct to diet in adult patients for the treatment of genetically confirmed familial
Ionis expands Surf Away+ event, marking 10 years of creating unique adaptive experiences for people with neurological diseases
CARLSBAD, Calif. --(BUSINESS WIRE)--Sep. 12, 2025-- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today celebrated 10 years of Surf Away+, an inclusive adaptive event for rare neurological disease communities. Originally created with the goal of providing people with spinal muscular atrophy (SMA)
Sign Up for News Alerts
For the latest on Ionis news and developments
– First and only investigational medicine to demonstrate a clinically meaningful and disease-modifying impact on this rare, often fatal neurological condition – – NDA submission planned in Q1 2026 – CARLSBAD, Calif. --(BUSINESS WIRE)--Sep. 22, 2025-- Ionis Pharmaceuticals, Inc.
CARLSBAD, Calif. --(BUSINESS WIRE)--Sep. 19, 2025-- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) and Sobi® today announced that TRYNGOLZA® (olezarsen) has been approved in the European Union (EU) as an adjunct to diet in adult patients for the treatment of genetically confirmed familial
CARLSBAD, Calif. --(BUSINESS WIRE)--Sep. 12, 2025-- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today celebrated 10 years of Surf Away+, an inclusive adaptive event for rare neurological disease communities. Originally created with the goal of providing people with spinal muscular atrophy (SMA)
Click here to read an important notice about a cybersecurity incident relating to services provided to WEX Health (an Ionis employee benefits plan administrator).